A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India

StatusRecruiting
PhasePhase 4
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 6 to 7
  2. Trial sites expanded: 2 → 6 locations
    • Eligibility criteria expanded, about 35 words
  3. Recruitment opened
    • Study sites: 0 to 2
    • Primary and study completion dates: Jan 11, 2028 to Jan 4, 2028
    • Start date changed from estimate of Jul 17, 2026 to Jul 24, 2026
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
438 trials monitored
See 32 trials at risk
Migraine
483 trials monitored
See 27 trials at risk
This is a multicenter, single-arm, open-label Phase 4 study evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult patients in India who have had an insufficient response, intolerance, or contraindication to triptans. It will enroll approximately 60 participants.
Trial Details
NCT Number NCT07685769
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Acute Treatment of Migraine
Related terms Migraine Disorders
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov